Table 4.
Sensitivity, specificity, PPV and NPV of CSF sCD146 and other molecules in the diagnosis of BBB damage
| Neuroinflammatory diseases | ||||
|---|---|---|---|---|
| Sensitivity (%) | Specificity (%) | PPV (%) | NPV (%) | |
| CSF sCD146 (<10.5 ng/mL) | 100 (562/562) | 93.1 (202/217) | 97.4 (562/577) | 100 (202/202) |
| QAlb (<5 × 10-3) | 46.3 (260/562) | 64.1 (139/217) | 76.9 (260/338) | 31.5 (139/441) |
| IgG synthesis (<30 mg/24 h) | 31.7 (178/562) | 86.6 (188/217) | 85.9 (178/207) | 32.9 (188/572) |
| IgG index (<0.85) | 69.6 (391/562) | 41.2 (120/217) | 80.2 (391/488) | 41.2 (120/291) |
| CSF-MBP (<3.5 μg/mL) | 54.7 (307/562) | 64.5 (140/217) | 79.9 (307/384) | 35.4 (140/395) |
| Serum MBP (<2.5 μg/mL) | 73.9 (415/562) | 55.8 (121/217) | 81.2 (415/511) | 45.1 (121/268) |
| OCB | 47 (264/562) | 81.6 (177/217) | 86.8 (264/304) | 37.3 (177/475) |
| sVCAM (<23.5 ng/mL) | 38.8 (78/202) | 100 (44/44) | 100 (78/78) | 26.2 (44/168) |
| sICAM (<22.4 pg/mL) | 74.4 (150/202) | 100 (44/44) | 100 (150/150) | 45.8 (44/96) |
| MMP2 (<41.6 ng/mL) | 72.2 (146/202) | 95.5 (42/44) | 98.6 (146/148) | 42.9 (42/98) |
| MMP9 (<0.95 ng/mL) | 28.9 (58/202) | 95.5 (42/44) | 96.7 (58/60) | 22.6 (42/186) |
| IL-1β (<8.76 pg/mL) | 13.3 (27/202) | 93.2 (41/44) | 90.0 (27/30) | 19.0 (41/216) |
| IL-17A (<49.9 pg/mL) | 41.1 (83/202) | 90.9 (40/44) | 95.4 (83/87) | 25.2 (40/159) |
| IFN-γ (<13.4 pg/mL) | 33.3 (67/202) | 100 (44/44) | 100 (67/67) | 24.6 (44/179) |
Abbreviations: PPV, positive predictive value, calculated from the number of neuroinflammatory patients who test positive relative to the total number of patients who test positive; NPV, negative predictive value, calculated from the number of NIND patients who test negative relative to the total number of patients who test negative.
The cut-off values of sCD146, sVCAM, sICAM, MMP2, MMP9, IL-1β, IL-17A and IFN-γ are represented by the mean ± 2SD.